Immune checkpoint inhibitors (ICIs; antibodies that block T cell co‐inhibitory receptors such as PD‐1 and CTLA‐4) have revolutionized the treatment of some cancers [1, 2, 3]. This evidence concerns the gene CTLA4 and cancer.